10-Q: KORU Medical Narrows Q3 Loss on Strong International Growth

KORU Medical Systems reported a significant reduction in net loss for Q3 2025, driven by robust international core revenue growth despite domestic declines.

Summary

• Net revenues for the three months ended September 30, 2025, increased by 27.2% to $10.4 million, compared to $8.2 million in the prior year period.
• For the nine months ended September 30, 2025, net revenues increased by 21.9% to $30.2 million, up from $24.8 million in the prior year period.
• International core revenues surged by 229.6% in Q3 2025 to $3.7 million and by 82.9% for the nine months to $8.3 million.
• Domestic core revenues decreased by 5.0% in Q3 2025 to $6.1 million, primarily due to lower orders from a US distributor and inventory reduction, but increased by 8.6% for the nine months to $20.1 million.
• Net loss significantly decreased by 50.8% to $0.8 million in Q3 2025 and by 52.3% to $2.2 million for the nine months ended September 30, 2025.
• Gross margin declined to 60.2% in Q3 2025 (from 63.4%) and 62.1% for the nine months (from 63.6%), attributed to higher manufacturing costs, geographic sales mix, and tariff charges.
• Research and development expenses decreased by 39.2% in Q3 2025 to $0.9 million and by 21.7% for the nine months to $3.2 million, reflecting lower project spend and severance.
• Cash and cash equivalents stood at $8.5 million as of September 30, 2025, a decrease from $9.6 million at December 31, 2024.
• Net cash used in operating activities for the nine months ended September 30, 2025, improved to $0.6 million from $1.3 million in the prior year period.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth, particularly internationally, and significantly reduced its net loss. While gross margins faced pressure and domestic sales declined in Q3, the overall financial improvement and positive shift in cash flow from financing activities indicate a positive trajectory. The mention of potential future capital raises is a point of caution but is framed within strategic growth.

Positives

• Total net revenues increased significantly by 27.2% in Q3 2025 and 21.9% for the nine months ended September 30, 2025.
• International core revenues showed exceptional growth, up 229.6% in Q3 and 82.9% for the nine months, driven by strategic market supply and new patient starts.
• Net loss was substantially reduced by 50.8% in Q3 2025 to $0.8 million and by 52.3% for the nine months to $2.2 million.
• Net cash used in operating activities decreased from $1.3 million in the prior year to $0.6 million for the nine months ended September 30, 2025, indicating improved operational efficiency.
• Net cash used in investing activities decreased from $1.4 million in the prior year to $0.5 million for the nine months ended September 30, 2025.
• Net cash provided by financing activities turned positive at $0.04 million for the nine months ended September 30, 2025, compared to cash used of $0.03 million in the prior year.
• Research and development expenses decreased by 39.2% in Q3 and 21.7% for the nine months, suggesting effective cost management or project prioritization.
• The loan and security agreement was amended to extend the maturity of the revolving credit facility to December 31, 2026, and the interest-only portion of the term loan facility to October 1, 2026, providing greater financial flexibility.

Negatives

• Domestic core revenues decreased by 5.0% in Q3 2025, primarily due to lower orders from a US distributor and inventory reduction.
• Gross margin declined to 60.2% in Q3 2025 (from 63.4%) and 62.1% for the nine months (from 63.6%), primarily due to higher manufacturing costs, geographic sales mix, and tariff charges.
• Selling, general and administrative expenses increased by 16.9% in Q3 and 9.7% for the nine months, driven by increases in compensation, bonus accruals, commissions, legal fees, and facility expenses.
• Cash and cash equivalents decreased by $1.1 million from $9.6 million at December 31, 2024, to $8.5 million at September 30, 2025.
• Inventory increased by $1.6 million from $2.8 million at December 31, 2024, to $4.4 million at September 30, 2025, which could indicate slower sales or anticipation of future demand.

Risks

• Uncertainties associated with inflation, tariffs, war, and other geopolitical conflicts.
• Fluctuations in customer ordering patterns.
• Availability and costs of raw materials and labor, and the company's ability to recover such costs.
• Variability in future operating results.
• Growth rates of new patient starts and the Immunoglobulin (Ig) market.
• Compliance with Food and Drug Administration (FDA) and foreign authority regulations and the outcome of regulatory audits.
• Introduction of competitive products.
• Acceptance of and demand for new and existing products.
• Ability to penetrate new markets.
• Success in enforcing and obtaining patents.
• Reimbursement-related risks.
• Government regulation of the home health care industry.
• Success of research and development efforts.
• Expanding the market of the FREEDOM™ System.
• Demand in the Subcutaneous Immunoglobulin (SCIg) market.
• Availability of sufficient capital if or when needed, with no assurance of obtaining required financing or capital.
• Dependence on key personnel.
• Impact of recent accounting pronouncements.
• Tariff-related charges are expected to have a gross margin impact of less than 100 basis points on an annualized basis, but actual results may differ from estimates.

Future Outlook

The company expects its cash on hand and cash flows from operations to be sufficient to meet its requirements for at least the next twelve months. However, continued execution of the longer-term strategic plan may necessitate drawing on the existing credit facility, taking on additional debt, or raising capital through the issuance of equity. Tariff-related charges are projected to have a gross margin impact of less than 100 basis points on an annualized basis, although actual results may vary.

Management Comments

• "Ended the third quarter of 2025 with $10.4 million in net revenues, a 27.2% increase compared to $8.2 million in the same period last year."
• "Growth in our international core business of 229.6% was offset by a decline in our domestic core business of 5.0%, as well as a decline in our pharma services and clinical trials business of 4.4%."
• "Our geographic mix within core revenues was impacted by a US distributor's purchase of KORU products from an international distributor."
• "At this time, we expect tariff-related charges to have a gross margin impact of less than 100 basis points on an annualized basis."
• "We expect that our cash on hand and cash flows from operations will be sufficient to meet our requirements at least through the next twelve months."
• "Continued execution on our longer-term strategic plan may require the Company to draw on our credit facility, take on additional debt, raise capital through issuance of equity, or utilize a combination of the above."

Industry Context

KORU Medical Systems operates in the specialized subcutaneous drug delivery market, primarily serving patients with Primary Immunodeficiency Diseases (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) requiring immunoglobulin therapy. The significant growth in international core business, partly driven by anticipated demands for prefilled conversion from vials, suggests a broader industry trend towards more convenient and patient-centric drug administration methods. The inherent variability in pharma services and clinical trials revenue reflects the project-based nature of supporting biopharmaceutical drug development.

Corporate Governance

Legal Proceedings

• The company is involved in legal proceedings, claims, and litigation arising in the ordinary course of business.
• The company is not presently a party to any litigation or other legal proceedings believed to be material to its financial condition.
• The company was previously under audit for tax year 2022 but has since received notification from the Internal Revenue Service that it is no longer under audit.

Stakeholder Impact

• Shareholders: Potential positive impact from strong revenue growth and reduced net loss, but diluted by declining gross margins and the possibility of future equity raises.
• Employees: Impacted by changes in stock-based compensation plans and potential for new hires (as indicated by increased SG&A expenses).
• Customers: International customers are experiencing strong supply, while US distributors are adjusting inventory and sourcing, indicating dynamic market conditions.
• Creditors: The extension of debt facility maturities provides more stability and reduces immediate repayment pressure.

Next Steps

• Continue execution on the longer-term strategic plan.
• Potentially draw on the credit facility, take on additional debt, or raise capital through equity issuance to fund future business activities and requirements.
• Monitor and manage the impact of tariff-related charges on gross margin.

Key Dates

Recommendation

KORU Medical Systems demonstrates promising revenue growth, particularly in international markets, and a significant reduction in net losses, which are positive indicators. However, the decline in domestic core revenue, pressure on gross margins due to manufacturing costs and tariffs, and the ongoing need for potential future capital raises introduce elements of uncertainty. The company's improved cash flow from operations and investing activities are encouraging, but the overall financial position still reflects a net loss. A 'hold' recommendation reflects the balance between these positive developments and the existing challenges and future capital needs.

Keywords

KORU Medical Systems, KRMD, Q3 2025, financial results, net revenues, net loss, international growth, domestic sales, gross margin, operating expenses, R&D, subcutaneous drug delivery, medical devices, FDA, PIDD, CIDP, pharma services, clinical trials, liquidity, capital resources, stock-based compensation, tariffs